BR112019003731A2 - aplicação de pridopidina para tratamento de distonias - Google Patents

aplicação de pridopidina para tratamento de distonias

Info

Publication number
BR112019003731A2
BR112019003731A2 BR112019003731A BR112019003731A BR112019003731A2 BR 112019003731 A2 BR112019003731 A2 BR 112019003731A2 BR 112019003731 A BR112019003731 A BR 112019003731A BR 112019003731 A BR112019003731 A BR 112019003731A BR 112019003731 A2 BR112019003731 A2 BR 112019003731A2
Authority
BR
Brazil
Prior art keywords
pridopidine
dystonias
treatment
application
individual
Prior art date
Application number
BR112019003731A
Other languages
English (en)
Portuguese (pt)
Inventor
Borowsky Beth
Eyal Eli
D Grachev Igor
Savola Juha-Matti
Forrest Gordon Mark
Hayden Michael
Papapetropoulos Spyridon
Original Assignee
Prilenia Therapeutics Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prilenia Therapeutics Dev Ltd filed Critical Prilenia Therapeutics Dev Ltd
Publication of BR112019003731A2 publication Critical patent/BR112019003731A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112019003731A 2016-08-24 2017-08-24 aplicação de pridopidina para tratamento de distonias BR112019003731A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662379175P 2016-08-24 2016-08-24
US201662395319P 2016-09-15 2016-09-15
PCT/US2017/048458 WO2018039475A1 (en) 2016-08-24 2017-08-24 Use of pridopidine for treating dystonias

Publications (1)

Publication Number Publication Date
BR112019003731A2 true BR112019003731A2 (pt) 2019-07-16

Family

ID=61246309

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019003731A BR112019003731A2 (pt) 2016-08-24 2017-08-24 aplicação de pridopidina para tratamento de distonias

Country Status (12)

Country Link
US (2) US11826361B2 (https=)
EP (1) EP3503890B1 (https=)
JP (2) JP7278210B2 (https=)
CN (1) CN110012661A (https=)
AU (1) AU2017315781B2 (https=)
BR (1) BR112019003731A2 (https=)
CA (1) CA3035099C (https=)
DK (1) DK3503890T3 (https=)
ES (1) ES3009437T3 (https=)
MX (1) MX2019002190A (https=)
PL (1) PL3503890T3 (https=)
WO (1) WO2018039475A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013536825A (ja) 2010-09-03 2013-09-26 イバックス・インターナショナル・ゲーエムベーハー ドパミン作動性安定化剤として有用なプリドピジンの重水素化類似体
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
HK1221646A1 (zh) 2013-06-21 2017-06-09 Teva Pharmaceuticals International Gmbh 高剂量普利多匹定用於治疗亨廷顿舞蹈症的用途
US11471449B2 (en) 2015-02-25 2022-10-18 Prilenia Neurotherapeutics Ltd. Use of pridopidine to improve cognitive function and for treating Alzheimer's disease
JP6887952B2 (ja) 2015-02-25 2021-06-16 プリレニア ニューロセラピューティクス リミテッド 認知機能を改善するため、およびアルツハイマー病を治療するためのプリドピジンの使用
EP4516356A3 (en) 2016-08-24 2025-05-14 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating functional decline
CA3035099C (en) 2016-08-24 2023-01-17 Prilenia Therapeutics Development Ltd. Use of pridopidine for treating dystonias
US12102627B2 (en) 2016-09-16 2024-10-01 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating rett syndrome
US12036213B2 (en) 2017-09-08 2024-07-16 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
JP2020533296A (ja) 2017-09-08 2020-11-19 プリレニア ニューロセラピューティクス リミテッド 薬物誘発性ジスキネジアを治療するためのプリドピジン
CN113395964A (zh) 2019-02-04 2021-09-14 普瑞尼亚神经治疗有限公司 用于帕金森氏病和与帕金森症相关的其它疾病的低剂量普利多匹定
CA3176917A1 (en) * 2020-05-04 2021-11-11 Prilenia Neurotherapeutics Ltd. Treatment of viral infection, disease or disorder using a selective s1r agonist
WO2024142058A1 (en) * 2022-12-27 2024-07-04 Prilenia Neurotherapeutics Ltd. Pridopidine for treating juvenile huntington's disease
WO2024258929A1 (en) * 2023-06-12 2024-12-19 Unravel Biosciences, Inc. Methods for treating diseases associated with taf1 loss of function
US20250281500A1 (en) * 2024-03-06 2025-09-11 Ovid Therapeutics Inc. Fused amino pyrimidine compounds and pridopidine for treatment of huntington’s disease

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9904724D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
ES2346452T3 (es) * 2004-06-08 2010-10-15 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Nuevas fenilpiperidinas/piperazinas disustituidas utilizadas como moduladores de la neurotransmision de la dopamina.
SE0401465D0 (sv) * 2004-06-08 2004-06-08 Carlsson A Research Ab New substituted piperdines as modulators of dopamine neurotransmission
CA2584831C (en) 2004-10-13 2013-09-17 Neurosearch Sweden Ab Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-n-propyl-piperidine
SE529246C2 (sv) * 2005-10-13 2007-06-12 Neurosearch Sweden Ab Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission
CN101711236B (zh) 2007-04-12 2012-10-31 Nsab神经研究瑞典公司分公司 表现出改善的心血管副作用特性的多巴胺受体稳定剂/调节剂的n-氧化物和/或二-n-氧化物衍生物
US8562488B2 (en) * 2009-10-05 2013-10-22 The Cleveland Clinic Foundation Systems and methods for improving motor function with assisted exercise
WO2011107583A1 (en) * 2010-03-04 2011-09-09 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders
JP2013536825A (ja) 2010-09-03 2013-09-26 イバックス・インターナショナル・ゲーエムベーハー ドパミン作動性安定化剤として有用なプリドピジンの重水素化類似体
BR112014005389A8 (pt) 2011-09-07 2018-04-03 Ivax Int Gmbh Sal cloridrato de 4- (3-metanossulfonil-fenil) -1- propil-piperidina em uma forma cristalina, composição farmacêutica compreendendo o mesmo e usos do dito sal
TWI579272B (zh) * 2011-12-08 2017-04-21 梯瓦製藥國際有限責任公司 普多比啶（ｐｒｉｄｏｐｉｄｉｎｅ）之氫溴酸鹽
US9744155B2 (en) 2012-03-28 2017-08-29 Ixcela, Inc. IPA as a therapeutic agent, as a protective agent, and as a biomarker of disease risk
AU2013243461A1 (en) 2012-04-04 2014-11-06 Teva Pharmaceuticals International Gmbh Pharmaceutical compositions for combination therapy
US20140037850A1 (en) * 2012-08-06 2014-02-06 General Electric Company Corrosion and wear resistant organic coatings
HK1221646A1 (zh) 2013-06-21 2017-06-09 Teva Pharmaceuticals International Gmbh 高剂量普利多匹定用於治疗亨廷顿舞蹈症的用途
MX377576B (es) 2014-01-22 2025-03-04 Prilenia Neurotherapeutics Ltd Formulaciones de pridopidina de liberación modificada.
TW201613859A (en) 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
MX2017008136A (es) 2014-12-22 2018-03-06 Teva Pharmaceuticals Int Gmbh Sal de l-tartrato de pridopidina.
JP6887952B2 (ja) 2015-02-25 2021-06-16 プリレニア ニューロセラピューティクス リミテッド 認知機能を改善するため、およびアルツハイマー病を治療するためのプリドピジンの使用
WO2016138135A1 (en) 2015-02-25 2016-09-01 Teva Pharmaceuticals International Gmbh Sigma-1 receptor modulators for treating huntington's disease
EP3324967A4 (en) 2015-07-22 2019-03-20 Prilenia Therapeutics Development Ltd. PRIDOPIDINE-BASED FORMULATIONS AND USE OF THE SAME
AR105434A1 (es) 2015-07-22 2017-10-04 Teva Pharmaceuticals Int Gmbh Proceso para preparar pridopidina
JP7034488B2 (ja) 2016-02-24 2022-03-14 プリレニア・ニューロセラピューティクス・エルティーディー プリドピジンを使用する神経変性眼疾患の治療
CA3035099C (en) 2016-08-24 2023-01-17 Prilenia Therapeutics Development Ltd. Use of pridopidine for treating dystonias
EP4516356A3 (en) 2016-08-24 2025-05-14 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating functional decline
CN109952100A (zh) 2016-09-15 2019-06-28 普瑞尼亚医疗发展有限公司 普利多匹定用于治疗焦虑和抑郁的用途
HUE058314T2 (hu) 2016-09-16 2022-07-28 Prilenia Neurotherapeutics Ltd Pridopidin alkalmazása Rett-szindróma kezelésére
WO2018053275A1 (en) 2016-09-16 2018-03-22 Teva Pharmaceuticals International Gmbh Use of pridopidine for the treatment of familial dysautonomia
CA3050700C (en) 2017-01-20 2023-10-03 Prilenia Neurotherapeutics Ltd. Use of pridopidine for the treatment of fragile x syndrome
SI4154882T1 (sl) 2017-08-14 2026-01-30 Prilenia Neurotherapeutics Ltd. Zdravljenje amiotrofične lateralne skleroze s pridopidinom
JP2020533296A (ja) 2017-09-08 2020-11-19 プリレニア ニューロセラピューティクス リミテッド 薬物誘発性ジスキネジアを治療するためのプリドピジン

Also Published As

Publication number Publication date
ES3009437T3 (en) 2025-03-26
JP7278210B2 (ja) 2023-05-19
EP3503890B1 (en) 2024-12-18
JP7278327B2 (ja) 2023-05-19
AU2017315781A1 (en) 2019-04-11
CA3035099C (en) 2023-01-17
WO2018039475A1 (en) 2018-03-01
CN110012661A (zh) 2019-07-12
EP3503890A4 (en) 2020-05-06
EP3503890A1 (en) 2019-07-03
US20190192496A1 (en) 2019-06-27
JP2021119189A (ja) 2021-08-12
JP2019524897A (ja) 2019-09-05
US11826361B2 (en) 2023-11-28
DK3503890T3 (da) 2025-01-27
AU2017315781B2 (en) 2021-01-28
WO2018039475A8 (en) 2018-10-04
US20240075021A1 (en) 2024-03-07
US12564582B2 (en) 2026-03-03
CA3035099A1 (en) 2018-03-01
MX2019002190A (es) 2019-09-11
PL3503890T3 (pl) 2025-03-24

Similar Documents

Publication Publication Date Title
BR112019003731A2 (pt) aplicação de pridopidina para tratamento de distonias
BR112017020895A2 (pt) inibidores de indolamina-2,3-dioxigenase para o tratamento de câncer
EA201792496A1 (ru) Способы лечения воспаления или нейропатической боли
CL2016001715A1 (es) Nuevos inhibidores de glutaminasa
BR112018003588A2 (pt) compostos e composições úteis para tratamento de distúrbios relacionados ao ntrk
BR112016022855A2 (pt) composições e métodos para modular a expressão de pkk
BR112019005040A2 (pt) aplicação de pridopidina para tratamento de síndrome de rett
PH12019501097A1 (en) Magl inhibitors
BR112017011900A2 (pt) tratamento de ataques com fosfatase alcalina recombinante
CR20160582A (es) Composición para tratar diabetes, que contienen un conjugado de análogo de insulina de acción prolongada y un conjugado de péptido insulinotrópico de acción prolongada
MX2015013948A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
MX383484B (es) Método para tratar el cáncer.
BR112017009584A2 (pt) tratamento de retinite pigmentosa com n-acetilcisteína amida
TN2019000150A1 (en) Magl inhibitors
MX2021011507A (es) Compuestos farmaceuticos para el tratamiento de trastornos mediados por complemento.
MX2020002645A (es) Pridopidina para el tratamiento de las discinesias inducidas por fármacos.
BR112015019564A2 (pt) tratamento de esclerose múltipla com laquinimod
MX2019001634A (es) Compuestos amidas, composiciones farmacéuticas de estos y métodos para utilizarlos.
MX389771B (es) Compuestos de minociclina para biodefensas.
BR112017024908A2 (pt) usos terapêuticos da 4-cloroquinurenina
CO2018008856A2 (es) Composiciones y métodos para el tratamiento de heridas crónicas
MX382044B (es) Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estrés.
BR112017001963A2 (pt) composição farmacêutica oral, seu processo de preparação e método de tratamento
MX2020005952A (es) Uso de mir101 o mir128 en el tratamiento de trastornos convulsivos.
CL2021003442A1 (es) Composición farmacéutica que comprende idelalisib y defactinib; y métodos para el tratamiento de cáncer.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B25D Requested change of name of applicant approved

Owner name: PRILENIA NEUROTHERAPEUTICS LTD. (IL)

B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: VIDE PARECER.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2789 DE 18-06-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.